RxDoctor Payments Data

Anjana Mary Jacob

Family · Memphis, TNNPI 1942842752

Payments from drug & device makers

$1,754in general payments, 2019–2025

Across 15 payments — averaging $116.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$271
  • Novo Nordisk$235
  • Gilead$234
  • Orphalan Inc$134
  • Ipsen Biopharmaceuticals, Inc$127
  • AbbVie$125
  • plus $630 from 6 others

What the payments were for

  • Food & beverage$1,754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Madrigal Pharmaceuticals2$271
Novo Nordisk2$235
Gilead2$234
Orphalan Inc1$134
Ipsen Biopharmaceuticals, Inc1$127
AbbVie1$125
AstraZeneca1$119
Eisai Inc.1$116
Intercept Pharmaceuticals, Inc.1$107
Mirum Pharmaceuticals, Inc.1$106
GSK1$104
VBI Vaccine (delaware) Inc.1$78

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,754 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$18,026
Medicare patients
166
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin64$201,605
VemlidyTenofovir Alafenamide30$42,865
Tacrolimus244$21,836
Envarsus XrTacrolimus47$17,143
PrografTacrolimus19$14,986
Mycophenolic AcidMycophenolate Sodium37$14,232
Sirolimus47$11,941
Ursodiol94$11,796
Trientine Hcl12$10,080
Entecavir93$7,470
Mycophenolate Mofetil84$3,866
Lactulose59$1,995
Acamprosate Calcium13$1,704
Spironolactone107$1,107
SpsSodium Polystyrene Sulfon/Sorb14$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$234$42,86530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →